ReviewDrugs1993
Safety and tolerability of fluoroquinolones.
Review in Drugs, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.Antimicrobial agents and chemotherapy · 2001Trial
- Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.Antimicrobial agents and chemotherapy · 1996Trial
- Use of oral fluoroquinolones in France between 2014 and 2023: a nationwide drug utilization study.JAC-antimicrobial resistance · 2025Article
- Hypoglycemia associated with fluoroquinolone: a pharmacovigilance analysis from 2014 to 2023 based on the FDA adverse event reporting system.Frontiers in medicine · 2025Article
- Mutant Prevention Concentration of Ciprofloxacin againstInternational journal of microbiology · 2019Article
- Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis.Gut and liver · 2014Article
- Moxifloxacin safety: an analysis of 14 years of clinical data.Drugs in R&D · 2012Article
- Non prescribed sale of antibiotics in Riyadh, Saudi Arabia: a cross sectional study.BMC public health · 2011Article
- Cellular and humoral immunodepression in vultures feeding upon medicated livestock carrion.Proceedings. Biological sciences · 2009Article
- Hypersensitivity reactions to fluoroquinolones.Current allergy and asthma reports · 2005Review
- Quinolone Resistance: Older Concepts and Newer Developments.Current infectious disease reports · 2001Article
- Toxicity of quinolones.Drugs · 1999Review
- Sparfloxacin: An Overview of Its Efficacy in ENT Infections.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 1997Article
- Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.Drugs · 1996Review
- Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.Drugs · 1995Review
- Fluoroquinolone toxicities. An update.Drugs · 1995Review
- Limited effects of temafloxacin compared with ciprofloxacin on T-lymphocyte function.Antimicrobial agents and chemotherapy · 1994Article
- Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.Drugs & aging · 1994Review
- Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events.Health securityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their introduction in the mid-1980s, the fluoroquinolones have been administered to more than 100 million patients. Generally, adverse effects reported in association with the fluoroquinolones have been those that could have been predicted by previous experience with non-fluorinated derivatives and by animal toxicity studies. Examples of such adverse events are CNS-related toxicity, upper gastrointestinal tract reactions and phototoxicity. Some adverse experiences in animals, notably cartilage toxicity, have been of minimal clinical importance. This should lead to a re-evaluation of the possible paediatric indications for the fluoroquinolones. With temafloxacin, which was withdrawn from clinical use in June 1992, new and serious adverse events were reported at a frequency of about 1 per 3500 patients treated. This frequency of adverse events is too low to be detected even in very careful analyses of phase III registration studies. Anaphylaxis, haemolytic anaemia and renal failure were the most striking adverse events reported with temafloxacin, and, in addition, hypoglycaemia and hepatic failure were reported. These reactions may be attributable to an immunological reaction in some patients. Because of the rarity of these reactions, they can be detected only by studies encompassing thousands of patients, usually during postmarketing surveillance. Safety monitoring of each new fluoroquinolone during its early clinical use is therefore recommended.
Indexed as
Identifiers
7689453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.